论文部分内容阅读
目的:观察替罗非班在老年非ST段抬高急性冠脉综合征(NSTEACS)介入治疗(PCI)的疗效及对血清可溶性CD40配体(sCD40L)水平的影响。方法:将80例经危险度分层为高危的老年NSTEACS患者行介入治疗,随机分为替罗非班组43例,对照组37例,观察住院期间及30d内的心血管不良事件(MACE),用酶联免疫吸附法(ELISA)法测定所有入选患者PCI前后血清sCD40L水平。结果:与对照组相比,替罗非班组住院期间及30d内MACE发生率有所降低;两组大出血发生率差异无统计学意义,替罗非班组轻度出血较对照组有所增加,但差异无统计学意义;替罗非班组治疗前后血清sCD40L水平显著降低。结论:替罗非班可减少MACE发生率,在老年NSTEACSPCI中疗效确切,能显著降低sCD40L的水平。
Objective: To observe the effect of tirofiban in elderly patients with non-ST-segment elevation acute coronary syndrome (PCI) and its effect on serum soluble CD40 ligand (sCD40L). Methods: Eighty elderly NSTEACS patients at risk for stratification were randomly divided into tirofiban group (n = 43) and control group (n = 37). Cardiovascular adverse events (MACE) were observed during hospitalization and within 30 days. Serum levels of sCD40L were measured by enzyme-linked immunosorbent assay (ELISA) in all patients before PCI. Results: Compared with the control group, the incidence of MACE was lower in the Tirofiban group during hospitalization and within 30 days. There was no significant difference in the incidence of major bleeding between the two groups. Mild bleeding in the Tirofiban group was higher than that in the control group The difference was not statistically significant; Tirofiban group before and after treatment serum sCD40L levels were significantly lower. CONCLUSION: Tirofiban can reduce the incidence of MACE and has an exact effect in elderly NSTEACSPCI, which can significantly reduce the level of sCD40L.